Vanguard Group’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-145,810
| Closed | -$58K | – | 4602 |
|
|
2023
Q3 | $58K | Hold |
145,810
| – | – | ﹤0.01% | 4393 |
|
|
2023
Q2 | $101K | Hold |
145,810
| – | – | ﹤0.01% | 4391 |
|
|
2023
Q1 | $1.15M | Hold |
145,810
| – | – | ﹤0.01% | 3874 |
|
|
2022
Q4 | $131K | Sell |
145,810
-199,384
| -58% | -$204K | ﹤0.01% | 4361 |
|
|
2022
Q3 | $376K | Sell |
345,194
-15,596
| -4% | -$20.4K | ﹤0.01% | 4292 |
|
|
2022
Q2 | $443K | Hold |
360,790
| – | – | ﹤0.01% | 4318 |
|
|
2022
Q1 | $852K | Sell |
360,790
-9,763
| -3% | -$23.2K | ﹤0.01% | 4260 |
|
|
2021
Q4 | $1.15M | Buy |
370,553
+29,098
| +9% | +$96.6K | ﹤0.01% | 4230 |
|
|
2021
Q3 | $1.39M | Buy |
341,455
+4,489
| +1% | +$18.7K | ﹤0.01% | 4167 |
|
|
2021
Q2 | $1.63M | Sell |
336,966
-22,193
| -6% | -$99.5K | ﹤0.01% | 4029 |
|
|
2021
Q1 | $1.86M | Sell |
359,159
-17,429
| -5% | -$121K | ﹤0.01% | 3876 |
|
|
2020
Q4 | $2.51M | Buy |
376,588
+22,866
| +6% | +$187K | ﹤0.01% | 3603 |
|
|
2020
Q3 | $3.6M | Sell |
353,722
-3,063
| -0.9% | -$36K | ﹤0.01% | 3303 |
|
|
2020
Q2 | $4.48M | Buy |
356,785
+280,875
| +370% | +$3.93M | ﹤0.01% | 3147 |
|
|
2020
Q1 | $832K | Buy |
75,910
+1,717
| +2% | +$11.5K | ﹤0.01% | 3545 |
|
|
2019
Q4 | $389K | Hold |
74,193
| – | – | ﹤0.01% | 3842 |
|
|
2019
Q3 | $536K | Sell |
74,193
-2,619
| -3% | -$23.9K | ﹤0.01% | 3803 |
|
|
2019
Q2 | $690K | Buy |
76,812
+10,534
| +16% | +$101K | ﹤0.01% | 3768 |
|
|
2019
Q1 | $649K | Buy |
66,278
+17,696
| +36% | +$195K | ﹤0.01% | 3726 |
|
|
2018
Q4 | $584K | Sell |
48,582
-19,654
| -29% | -$285K | ﹤0.01% | 3706 |
|
|
2018
Q3 | $1.1M | Buy |
68,236
+1,687
| +3% | +$40.1K | ﹤0.01% | 3699 |
|
|
2018
Q2 | $2.42M | Buy |
66,549
+1,060
| +2% | +$36.7K | ﹤0.01% | 3441 |
|
|
2018
Q1 | $2.04M | Buy |
65,489
+16,009
| +32% | +$509K | ﹤0.01% | 3458 |
|
|
2017
Q4 | $1.92M | Buy |
49,480
+8,637
| +21% | +$226K | ﹤0.01% | 3430 |
|
|
2017
Q3 | $870K | Hold |
40,843
| – | – | ﹤0.01% | 3619 |
|
|
2017
Q2 | $821K | Buy |
40,843
+14,074
| +53% | +$291K | ﹤0.01% | 3611 |
|
|
2017
Q1 | $598K | Buy |
26,769
+23,188
| +648% | +$364K | ﹤0.01% | 3719 |
|
|
2016
Q4 | $28K | Hold |
3,581
| – | – | ﹤0.01% | 4060 |
|
|
2016
Q3 | $75K | Sell |
3,581
-2,251
| -39% | -$54.3K | ﹤0.01% | 4004 |
|
|
2016
Q2 | $151K | Hold |
5,832
| – | – | ﹤0.01% | 3982 |
|
|
2016
Q1 | $215K | Hold |
5,832
| – | – | ﹤0.01% | 3944 |
|
|
2015
Q4 | $259K | Hold |
5,832
| – | – | ﹤0.01% | 3973 |
|
|
2015
Q3 | $454K | Buy |
5,832
+2,020
| +53% | +$156K | ﹤0.01% | 3878 |
|
|
2015
Q2 | $453K | Buy |
+3,812
| New | +$518K | ﹤0.01% | 3889 |
|
Other funds holding BLPH
Vanguard Group's BLPH Position: Q4 2023 in Review
Vanguard Group sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q4 2023, closing a stake of 145,810 shares — an estimated $58K sold.
Vanguard Group first reported a position in BLPH in Q2 2015 and held it in 34 quarters. The position peaked at $4.48M in Q2 2020. 2 funds tracked by Wall St. Rank hold BLPH as of Q4 2023.
- Vanguard Group reported no remaining Bellerophon Therapeutics, Inc. position as of Q4 2023 after selling out during the quarter.
- Vanguard Group sold 145,810 Bellerophon Therapeutics, Inc. shares in Q4 2023, an estimated $58K.
- Vanguard Group first reported a position in Bellerophon Therapeutics, Inc. in Q2 2015 and held it in 34 quarters.
- Vanguard Group's Bellerophon Therapeutics, Inc. position peaked at $4.48M in Q2 2020.
- 2 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q4 2023.
Based on Vanguard Group's 13F filing for Q4 2023, filed 14 Feb 2024.